# Leprosy Skin Test Antigens Trial

> **NCT00128193** · PHASE2 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 260 (actual)

## Conditions studied

- Leprosy

## Interventions

- **BIOLOGICAL:** Tuberculin, Purified Protein Derivative
- **OTHER:** MLSA-LAM
- **OTHER:** MLCwA
- **BIOLOGICAL:** Tuberculin, Purified Protein Derivative
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT00128193
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-04
- **Primary completion:** 2009-09
- **Final completion:** 2009-09
- **Target enrollment:** 260 (ACTUAL)
- **Last updated:** 2014-12-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00128193

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00128193, "Leprosy Skin Test Antigens Trial". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT00128193. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*